Jubilant Pharmova Ltd - 530019 - Certificate Under Regulation 40 Of The SEBI Listing Regulations
As per Regulation 40(9) and Regulation 40(10) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a Certificate obtained from a Practising Company Secretary for the period ended March 31, 2021. Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Intimation of Notice published in newspapers in terms of SEBI Circular No. SEBI/HO/MIRSD/DOS3/CIR/P/2018/139 dated November 6, 2018 Jubilant Pharmova Ltd - 530019 - Shareholding for the Period Ended March 31, 2021
Jubilant Pharmova Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here Jubilant Pharmova Ltd - 530019 - Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a communication pertaining to development of a novel oral formulation of Remdesivir with successful completion of safety and pharmacokinetic/absorption studies. We request you to take the same on record. Jubilant Pharmova Ltd - 530019 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1560 Name of the Signatory :- Rajiv ShahDesignation :- Company Secretary and Compliance Officer Jubilant Pharmova Ltd - 530019 - Compliance Certificate Pursuant To Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we certify that M/s Alankit Assignments Limited, a Category-I Registrar and Share Transfer Agent, registered with the Securities and Exchange Board of India vide Registration No.: INR000002532, is the Registrar and Share Transfer Agent (the 'RTA') of Jubilant Pharmova Limited (the 'Company') and all activities in relation to both physical and electronic share transfer facility of the Company are being maintained by the RTA. Jubilant Pharmova Ltd - 530019 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, we are enclosing a Confirmation Certificate for the quarter ended March 31, 2021 received from M/s Alankit Assignments Limited, Registrar and Share Transfer Agent of the Company. Jubilant Pharmova Ltd - 530019 - Undertaking Under Regulation 57(2) Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015
Pursuant to the provisions of Regulation 57(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has provided all the documents and intimations required to be submitted to the Debenture Trustee i.e. Axis Trustee Services Limited during the Financial Year 2020-21 in terms of the Debenture Trust Deed and the SEBI (Issue and Listing of Debt Securities) Regulations, 2008. Jubilant Pharmova Ltd - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that a share certificate has been reported to be lost by the shareholder as per the attachment. The shareholder has requested for issuance of duplicate share certificate in lieu of the original. We propose to issue Duplicate Share Certificate to the shareholder on receipt of the requisite documents. We request you to caution your members not to deal in or make any transaction in these shares. This is for your information and record. Jubilant Pharmova Ltd - 530019 - Closure of Trading Window
Pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company will be closed for 'Designated Persons' from Thursday, March 25, 2021 and the same shall remain closed till 48 hours after announcement of the financial results for the quarter and year ending March 31, 2021 to the Stock Exchanges. Accordingly, the Designated Persons have been intimated not to trade in the securities of the Company during the aforesaid period of closure of Trading Window. This is for your information and records.